Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone app study to track rare swelling attacks cancelled

NCT ID NCT05304091

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to learn more about the unpredictable swelling attacks in people with bradykinin-mediated angioedema, a rare condition that can cause life-threatening airway swelling. Participants would have used a smartphone app daily to report attacks and possible triggers. The goal was to identify patterns over time and factors that might bring on an attack. However, the study was withdrawn before enrolling any participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Expected to start

Aug 2022

An estimate. Start dates often move.

Expected to finish

Aug 2023

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with bradykinin-mediated angioedema, aged 18 years or older, followed in the internal medicine department of the Lille University Hospital.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of bradykinin-mediated angioedema * Age \> 18 * Having a smartphone * Non opposition to answer the questionnaire Exclusion Criteria: * Patients with other type (histaminergic) angioedema * Patient unable or unwilling to use a smartphone application * Opposition to the research * Minor or protected adult * Person deprived of liberty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bradykinin-mediated angioedema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

angioedema hereditary angioedema non-histaminic angioedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bradykinin-mediated angioedema

More trials for these conditions

Other studies related to the condition(s) this trial covers.